6-氯-5-甲氧基吡啶-2-胺 | 886371-76-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 6-氯-5-甲氧基吡啶-2-胺
• 英文名称: 6-chloro-5-methoxy-pyridin-2-amine
• 英文别名: 6-chloro-5-(methyloxy)-2-pyridinamine；6-Chloro-5-methoxypyridin-2-amine
• CAS: 886371-76-2
• 化学式: C₆H₇ClN₂O
• mdl: MFCD07374878
• 分子量: 158.587
• InChiKey: XYRKDHDEOIXQCU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.166
• 拓扑面积：
  48.1
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 海关编码：
  2933399090

反应信息

• 作为反应物：
  描述：

  6-氯-5-甲氧基吡啶-2-胺 在 (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride 、 盐酸羟胺 、 potassium carbonate 、 三乙胺 、 N,N-二异丙基乙胺 作用下， 以 1,4-二氧六环 、 甲醇 、 乙醇 、 水 、 乙腈 为溶剂， 反应 19.5h， 生成 N-[5-(4-ethoxyphenyl)-6-methoxy-[1,2,4]triazolo[1,5-a]pyridin-2-yl]cyclopropanecarboxamide
  参考文献：
  名称：

  Triazolopyridines as Selective JAK1 Inhibitors: From Hit Identification to GLPG0634

  摘要：

  Janus kinases (JAK1, JAK2, JAK3, and TYK2) are involved in the signaling of multiple cytokines important in cellular function. Blockade of the JAK-STAT pathway with a small molecule has been shown to provide therapeutic immunomodulation. Having identified JAK1 as a possible new target for arthritis at Galapagos, the compound library was screened against JAK1, resulting in the identification of a triazolopyridine-based series of inhibitors represented by 3. Optimization within this chemical series led to identification of GLPG0634 (65, filgotinib), a selective JAK1 inhibitor currently in phase 2B development for RA and phase 2A development for Crohns disease (CD).

  DOI：

  10.1021/jm501262q

文献信息

• [EN] PROLYL HYDROXYLASE INHIBITORS<br/>[FR] INHIBITEURS DE LA PROLYL HYDROXYLASE
  申请人：GLAXOSMITHKLINE LLC

  公开号：WO2010059549A1

  公开（公告）日：2010-05-27

  The invention described herein relates to certain 2,4-dioxo-l,2,3,4-tetrahydro-7- quinazolinecarboxamide derivatives of formula (I) which are antagonists of HIF prolyl hydroxylases and are useful for treating diseases benefiting from the inhibition of this enzyme, anemia being one example.

  本发明涉及某些公式（I）的2,4-二氧代-1,2,3,4-四氢-7-喹唑啉羧酰胺衍生物，这些衍生物是HIF脯氨酸羟化酶的拮抗剂，对于治疗受益于抑制该酶的疾病是有用的，贫血就是一个例子。
• N,N-bis-heteroaryl methylamines: Potent anti-mitotic and highly cytotoxic agents
  作者：Ilhem Khelifi、Timothée Naret、Abdallah Hamze、Jérome Bignon、Hélène Levaique、Maria Concepcion Garcia Alvarez、Joëlle Dubois、Olivier Provot、Mouad Alami

  DOI：10.1016/j.ejmech.2019.02.038

  日期：2019.4

  quinazoline ring is possible and often beneficiary for a high level of cytotoxicity. We have also showed that a carbazole or an indole nucleus are very effective as B-rings in this series, leading to anti-cancer drugs 1 having a sub-nanomolar level of cytotoxicity (1a: IC50 = 70 pM against HCT116 cells). 1a also display a high level of cytotoxicity against four other human cancer cells and inhibited tubulin assembly

  描述了一系列N，N-双-杂环-甲基胺1的合成和评价，其为异氮杂紫红素类似物。已证明用喹啉或喹唑啉环代替CA-4，iso CA-4和异氮杂紫宁中存在的3,4,5-三甲氧基苯基A-环是可能的，并且对于高水平的细胞毒性通常是有益的。我们还表明，咔唑或吲哚核作为该系列中的B环非常有效，导致抗癌药物1的细胞毒性水平低于纳摩尔水平（1a：IC 50  = 70 pM，针对HCT116细胞）。1a还显示出对其他四种人类癌细胞的高细胞毒性，并以微摩尔水平抑制了微管蛋白的组装。此外，浓度为5 nM时，1a使细胞周期停滞在细胞周期的G2 / M期，并诱导HCT116细胞凋亡。还显示在几个小时后，浓度为10 nM的1a完全破坏了Matrigel上的内皮网络形成。
• IMIDAZOL (1,2-A)PYRIDINES AND RELATED COMPOUNDS WITH ACTIVITY AT CANNABINOID CB2 RECEPTORS
  申请人：Olsson Roger

  公开号：US20110206607A1

  公开（公告）日：2011-08-25

  Disclosed herein are compounds of Formula (I), or a pharmaceutically acceptable salt, ester, amide, thereof; and methods of modulating the activity of a cannabinoid CB2 receptor comprising contacting a compound of Formula I with the cannabinoid CB2 receptor. Also disclosed are methods of imaging of a tissue by positron emission tomography, the method comprising administering to the subject a compound of Formula I, wherein the compound comprises a radioisotope. Also disclosed are methods of measuring the relative concentration of cannabinoid CB2 receptors in tissue of a subject, by using a compound of Formula I which comprises a radioisotope. In addition, method of diagnosing a disorder in a subject are disclosed.

  本文公开了I式化合物，或其药学上可接受的盐、酯、酰胺等；以及调节大麻素CB2受体活性的方法，包括将I式化合物与大麻素CB2受体接触。还公开了通过正电子发射断层扫描成像组织的方法，该方法包括向受试者注射I式化合物，其中该化合物包含放射性同位素。还公开了通过使用含有放射性同位素的I式化合物来测量受试者组织中大麻素CB2受体的相对浓度的方法。此外，还公开了一种诊断受试者疾病的方法。
• Prolyl Hydroxylase Inhibitors
  申请人：Gotchev Dimitar B.

  公开号：US20100298324A1

  公开（公告）日：2010-11-25

  The invention described herein relates to certain 4-oxo-2-thioxo-1,2,3,4-tetrahydro-7-quinazolinecarboxamide derivatives of formula (I) which are antagonists of HIF prolyl hydroxylases and are useful for treating diseases benefiting from the inhibition of this enzyme, anemia being one example.

  本发明涉及一些公式（I）所示的4-氧代-2-硫代-1，2，3，4-四氢-7-喹唑啉羧酰胺衍生物，它们是HIF脯氨酸羟化酶的拮抗剂，并且用于治疗受益于抑制该酶的疾病，贫血是其中的一个例子。
• PROLYL HYDROXYLASE INHIBITORS
  申请人：GlaxoSmithKline LLC

  公开号：EP2240178A1

  公开（公告）日：2010-10-20